Literature DB >> 33118435

Pharmacogenomics in the UK National Health Service: opportunities and challenges.

Richard M Turner1, William G Newman2, Elvira Bramon3, Christine J McNamee1, Wai Lup Wong4, Siraj Misbah5, Sue Hill6, Mark Caulfield7, Munir Pirmohamed1.   

Abstract

Despite increasing interest in pharmacogenomics, and the potential benefits to improve patient care, implementation into clinical practice has not been widespread. Recently, there has been a drive to implement genomic medicine into the UK National Health Service (NHS), largely spurred on by the success of the 100,000 Genomes Project. The UK Pharmacogenetics and Stratified Medicine Network, NHS England and Genomics England invited experts from academia, the healthcare sector, industry and patient representatives to come together to discuss the opportunities and challenges of implementing pharmacogenomics into the NHS. This report highlights the discussions of the workshop to provide an overview of the issues that need to be considered to enable pharmacogenomic medicine to become mainstream within the NHS.

Entities:  

Mesh:

Year:  2020        PMID: 33118435     DOI: 10.2217/pgs-2020-0091

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  5 in total

1.  A blockchain-based framework to support pharmacogenetic data sharing.

Authors:  F Albalwy; J H McDermott; W G Newman; A Brass; A Davies
Journal:  Pharmacogenomics J       Date:  2022-07-22       Impact factor: 3.245

2.  Resource allocation in genetic and genomic medicine.

Authors:  J Buchanan; I Goranitis; I Slade; A Kerasidou; M Sheehan; K Sideri; S Wordsworth
Journal:  J Community Genet       Date:  2022-10

Review 3.  Emerging technologies and their impact on regulatory science.

Authors:  Elke Anklam; Martin Iain Bahl; Robert Ball; Richard D Beger; Jonathan Cohen; Suzanne Fitzpatrick; Philippe Girard; Blanka Halamoda-Kenzaoui; Denise Hinton; Akihiko Hirose; Arnd Hoeveler; Masamitsu Honma; Marta Hugas; Seichi Ishida; George En Kass; Hajime Kojima; Ira Krefting; Serguei Liachenko; Yan Liu; Shane Masters; Uwe Marx; Timothy McCarthy; Tim Mercer; Anil Patri; Carmen Pelaez; Munir Pirmohamed; Stefan Platz; Alexandre Js Ribeiro; Joseph V Rodricks; Ivan Rusyn; Reza M Salek; Reinhilde Schoonjans; Primal Silva; Clive N Svendsen; Susan Sumner; Kyung Sung; Danilo Tagle; Li Tong; Weida Tong; Janny van den Eijnden-van-Raaij; Neil Vary; Tao Wang; John Waterton; May Wang; Hairuo Wen; David Wishart; Yinyin Yuan; William Slikker
Journal:  Exp Biol Med (Maywood)       Date:  2021-11-16

4.  The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.

Authors:  Isabelle Austin-Zimmerman; Marta Wronska; Baihan Wang; Haritz Irizar; Johan H Thygesen; Anjali Bhat; Spiros Denaxas; Ghazaleh Fatemifar; Chris Finan; Jasmine Harju-Seppänen; Olga Giannakopoulou; Karoline Kuchenbaecker; Eirini Zartaloudi; Andrew McQuillin; Elvira Bramon
Journal:  Genes (Basel)       Date:  2021-11-03       Impact factor: 4.096

5.  Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review.

Authors:  John H McDermott; Stuart Wright; Videha Sharma; William G Newman; Katherine Payne; Paul Wilson
Journal:  Front Med (Lausanne)       Date:  2022-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.